Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2b randomized double-blind placebo-controlled trial of oral infigratinib in infants and young children with achondroplasia
jRCT2051260134Phase 2Not yet recruiting
- Sponsor
- QED Therapeutics
- Start
- Jul 2026
- Modality
- Small Molecules
01
Overview
Phase 2, randomised, double-blind trial in achondroplasia (ACH) comparing Infigratinib arm with Placebo arm (2 arms). Primary endpoints: Safety (Phase 2b portion) and Change in body length Z-score at Week 52 (Phase 2b portion). Planned start Jul 2026; status: not yet recruiting.
02
Drugs
infigratinib
03
Conditions
achondroplasia (ACH)
Beyond the preview
Go deeper on jRCT2051260134.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2051260134.